The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakayama, T.
Right arrow Articles by Yoshie, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakayama, T.
Right arrow Articles by Yoshie, O.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2003, 170: 1136-1140.
Copyright © 2003 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: Profile of Chemokine Receptor Expression on Human Plasma Cells Accounts for Their Efficient Recruitment to Target Tissues 1

Takashi Nakayama*, Kunio Hieshima*, Dai Izawa*, Youichi Tatsumi{dagger}, Akihisa Kanamaru{dagger} and Osamu Yoshie2,*

Departments of * Microbiology and {dagger} Internal Medicine III, Kinki University School of Medicine, Osaka, Japan


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We systematically examined the repertoire of chemokine receptors expressed by human plasma cells. Fresh bone marrow plasma cells and myeloma cells consistently expressed CXCR4, CXCR6, CCR10, and CCR3. Accordingly, plasma cells responded to their respective ligands in chemotaxis and very late Ag-4-dependent cell adhesion to fibronectin. Immobilized CXC chemokine ligand (CXCL)16, a novel transmembrane-type chemokine and CXCR6 ligand, also directly induced adhesion of plasma cells without requiring G{alpha}i signaling or divalent cations. Furthermore, we revealed consistent expression of CXCL12 (CXCR4 ligand), CXCL16 (CXCR6 ligand), and CC chemokine ligand 28 (CCR10 and CCR3 ligand) in tissues enriched with plasma cells including bone marrow, and constitutive expression of CXCL12, CXCL16, and CC chemokine ligand 28 by cultured human bone marrow stromal cells. Collectively, plasma cells are likely to be recruited to bone marrow and other target tissues via CXCR4, CXCR6, CCR10, and CCR3. CXCR6 may also contribute to tissue localization of plasma cells through its direct binding to membrane-anchored CXCL16.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Chemokines play important roles in innate and acquired immunity by inducing directed migration of various types of leukocytes through interactions with a group of seven-transmembrane, G protein-coupled receptors (1). Accumulating evidence has demonstrated that chemokines and their receptors are crucial in trafficking and tissue microenvironmental localization of various lymphocyte classes and subsets (1). Thus, upon differentiation, maturation, and activation, cells of the lymphoid lineages dynamically change their expression profiles of chemokine receptors, leading to their specific migration programs to new sets of chemokines (1).

Plasma cells represent the end stage of B cell differentiation and function as the factories for Ab production. Plasma cells from immunized mice demonstrated up-regulation of CXCR4 and down-regulation of CXCR5 and CCR7 (2, 3). Furthermore, plasma cells in chimeric mice reconstituted with CXCR4-deficient fetal liver cells were mislocalized within the spleen, found in elevated numbers in the blood, and failed to accumulate in the bone marrow (2). Thus, CXCR4 and its ligand CXC chemokine ligand (CXCL)312 play a major role in the localization of plasma cells within splenic red pulp and lymph node medullary cords as well as in the bone marrow (2). Furthermore, IgA-producing cells but not those producing IgG or IgM in mice express CCR9 and efficiently respond to its ligand CC chemokine ligand (CCL)25, which is selectively expressed by cryptic epithelial cells in the small intestine (4).

Recently, we have found that EBV-immortalized human B cells consistently up-regulate CCR6 and CCR10 and down-regulate CXCR4 and CXCR5 (5). We have further shown that the EBV-encoded latent proteins are responsible for up-regulation of CCR6 and down-regulation of CXCR4 (5). However, the up-regulation of CCR10, whose expression in normal B cells has not been reported so far (6), or the down-regulation of CXCR5 could not be explained by the effects of the EBV-encoded latent proteins (5). Because EBV-immortalized B cells resemble plasma cells, we speculated that their differentiation stages fixed by immortalization with EBV may be responsible for CCR10 up-regulation and CXCR5 down-regulation. Indeed, recent studies have consistently shown CXCR5 down-regulation in mouse plasma cells (2, 3). These considerations prompted us to examine the full repertoire of chemokine receptors expressed by human plasma cells. In this study, we report that human bone marrow plasma cells and myeloma cells selectively express CXCR4, CXCR6, CCR10, and CCR3, and that tissues known to be enriched with plasma cells as well as cultured human bone marrow stromal cells constitutively express CXCL12 (CXCR4 ligand) (7), CXCL16 (CXCR6 ligand) (8, 9), and CCL28 (CCR10 and CCR3 ligand) (10, 11).


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cells and cytokines

RPMI8226 (JCRB0034), KMS-12BM (JCRB0429), KMS-12PE (JCRB0430), and KHM-1B (JCRB0133) were human myeloma cell lines obtained from Health Science Research Resources Bank (Sennan, Osaka, Japan). Human bone marrow irradiated stromal cells were purchased from Takara Biomedicals (Kyoto, Japan) (n = 2). Peripheral blood samples were obtained from healthy adult donors (n = 3) and patients with multiple myeloma (n = 3). Bone marrow samples were obtained from adult donors (n = 7) and also purchased from Takara Biomedicals (n = 5). Informed consents were obtained from all donors. Mononuclear cells were isolated by centrifugation on Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) and stored at -80°C until use. All human recombinant cytokines were purchased from PeproTech (Rocky Hill, NJ).

RT-PCR

This was conducted as described previously (5). cDNA samples from various human tissues were purchased from Clontech (Palo Alto, CA). Primers for the chemokine receptors and G3PDH were described previously (5). Primers for chemokines were as follows: +5'-CCCTCTGTGAGATCCGTCTTTGGCCT-3' and -5'-TCTGATTGGAACCTGAACCCCTGCTG-3' for CXCL12; +5'-CGTCACTGGAAGTTGTTATTGTGGT-3' and -5'-TGGTAGGAAGTAAATGCTTCTGGTG-3' for CXCL16; +5'-ACCACCTCTCACGCCAAAGCTCACAC-3' and -5'-CGGCACAGATATCCTTGGCCAGTTTG-3' for CCL11; +5'-CAACCTTCTGCAGCCTCCTG-3' and -5'-CCATTTTCCTTAGCATCCCA-3' for CCL27; and +5'-AGAAGCCATACTTCCCATTGC-3' and -5'-AGCTTGCACTTTCATCCACTG-3' for CCL28. Real-time PCR was performed using TaqMan assay and 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). Conditions for PCR included 50°C for 2 min, 95°C for 10 min, and 50 cycles of 95°C for 15 s (denaturation) and 60°C for 1 min (annealing/extension). The primers for chemokines were as follows: +5'-CCATGCCGATTCTTCGAAAG-3' and -5'-TTCAGCCGGGCTACAATCTG-3' for CXCL12; +5'-CGCCATCGGTTCAGTTCAT-3' and -5'-ACACACGCTCCAGGAAAGGA-3' for CXCL16; and +5'-CAGAGAGGACTCGCCATCGT-3' and -5'-TGTGAAACCTCCGTGCAACA-3' for CCL28. The probes for chemokines were as follows: +5'-CATCTCAAAATTCTCAACACTCCAAACTGTGCC-3' for CXCL12; +5'-ACCATCGGTGTCTATACTACACGAGGTTCCAG-3' for CXCL16; and +5'-CTTGGCTGTCTGTGCGGCCCTACAT-3' for CCL28. The probes were labeled with reporter fluorescent dye 6-FAM at the 5' end. Primers and fluorogenic probes for G3PDH were from TaqMan kit (Applied Biosystems). Quantification of chemokine expression was obtained using sequence detector system software (Applied Biosystems).

Flow cytometric analysis

The following murine mAbs were purchased from R&D Systems (Minneapolis, MN): anti-CXCR3 (clone 49801.111), anti-CXCR6 (clone 56811.11), anti-CCR3 (clone 444.11), anti-CCR6 (clone 53103.111), anti-CXCR4 (clone 44717.111), and anti-CXCR5 (clone 51505.111). Anti-CCR7 (2H7), PE-labeled anti-CD38 (HIT2), and Cy5-labeled CD45 (HI30) were purchased from BD Biosciences (Mountain View, CA). Rabbit anti-CCR10 was purchased from BIOCARTA (San Diego, CA). Isotype controls were purchased from DAKO (Kyoto, Japan). Cells were washed with PBS containing 2% FBS and reacted for 30 min with each mAb. After washing, cells were reacted with FITC-conjugated sheep (F(ab')2) anti-mouse IgG (Sigma-Aldrich, St. Louis, MO). In some experiments, cells were double stained with PE-labeled anti-CD38 and Cy5-labeled anti-CD45. For intracellular staining of CCR10, cells fixed and permeabilized with 2% paraformaldehyde and 0.1% Triton X-100 were indirectly stained with anti-CCR10 and FITC-labeled goat anti-rabbit IgG (Sigma-Aldrich). After staining, cells were analyzed on FACSCalibur (BD Biosciences) with appropriate gatings and quantitated in comparison with isotype control Abs. Dead cells were gated out by staining with propidium iodide.

Chemotaxis assay

All recombinant chemokines were purchased from R&D Systems. Migration assays for fresh human bone marrow mononuclear cells were conducted using Transwell plates with 8-µm pore size (Corning, Corning, NY) as described previously (5).

Cell adhesion assays

Cell adhesion to immobilized fibronectin was determined as described previously (12). The extracellular domain of human CXCL16/SR-PSOX (13) was subcloned into pDREF-SEAP (His)6-Hyg expression vector (14), and CXCL16 fused at the C terminus with secreted form of placental alkaline phosphatase (SEAP), or CXCL16-SEAP, was generated by transfection to HEK293 cells. Cell adhesion to immobilized CXCL16 was determined essentially as described previously (14).

ELISA

Human bone marrow stromal cells were seeded in 24-well plates at a density of 1 x 105 cells/well and cultured without or with 10 ng/ml IL-1{beta}. Measurement of CXCL12 and CCL28 in the culture supernatants was conducted using ELISA kits purchased from R&D Systems. For standardization of assay, serially diluted recombinant CXCL12 or CCL28 was included in each ELISA plate.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Consistent expression of CXCR4, CXCR6, CCR10, and CCR3 in plasma cells and myeloma cells

To gain an insight into the full repertoire of chemokine receptors expressed by human plasma cells, we first examined chemokine receptor expression in a panel of four human myeloma cell lines. RT-PCR analysis using specific primer sets for all known 18 chemokine receptors (CXCR1~6, CCR1~10, XCR1, and CX3CR1) (1) revealed that the myeloma cell lines were consistently positive for CXCR4, CXCR6, CCR10, and CCR3. Staining of these myeloma cell lines with specific Abs for various chemokine receptors and flow cytometric analysis verified the RT-PCR results (data not shown).

After getting a consensus profile of chemokine receptor expression in human myeloma cell lines, we proceeded to examine the expression of selected chemokine receptors on human bone marrow plasma cells. Plasma cells in bone marrow mononuclear cells could be identified by the expression of high levels of CD38 on their surface (15, 16). We confirmed that CD38high cells sorted from bone marrow mononuclear cells had the typical plasma cell morphology (Fig. 1a). As shown in Fig. 1a, plasma cells in the bone marrow expressed CXCR4 and CXCR6 at high levels, CCR10 at intermediate levels, CCR3 at low levels, and CXCR5, CCR6, and CCR7 at marginal levels. We found no significant differences in the expression levels of these chemokine receptors between CD38highCD45+ immature and CD38highCD45- mature plasma cells (15, 16) (data not shown).



View larger version (33K):
[in this window]
[in a new window]
 
FIGURE 1. Flow cytometric analysis for expression of chemokine receptors in fresh plasma cells and myeloma cells. a, Bone marrow mononuclear cells obtained from adult donors were triple stained for CD38, CD45, and indicated chemokine receptors, and analyzed by flow cytometry. Representative results from three donors are shown. May-Giemsa staining of CD38high cells sorted from bone marrow mononuclear cells was also shown. b, PBMC obtained from healthy adult donors and myeloma patients were double stained for CD38 and indicated chemokine receptors, and analyzed by flow cytometry. Representative results from three patients with multiple myeloma are shown.

 
We also conducted flow cytometric analysis on the expression of chemokine receptors on myeloma cells present in the peripheral blood of patient with multiple myeloma. As shown in Fig. 1b, PBMC from patients with multiple myeloma but not those from healthy adult donors contained a substantial fraction of cells expressing CD38 at high levels. We confirmed that these cells were also positive for another plasma cell marker CD138 (data not shown) (15, 16). These cells that represented floating myeloma cells in PBMC of myeloma patients also consistently expressed CXCR4 and CXCR6 at high levels, CCR10 at intermediate levels, and CCR3 at low levels (Fig. 1b).

Responses of plasma cells to the ligands of CXCR4, CXCR6, CCR10, and CCR3

We next examined chemotactic responses of bone marrow plasma cells to CXCL12 (CXCR4 ligand), CXCL13 (CXCR5 ligand), CXCL16 (CXCR6 ligand), CCL11 (CCR3 ligand), CCL27 (CCR10 ligand), and CCL28 (CCR10 and CCR3 ligand) (1). As shown in Fig. 2a, CXCL12, CXCL16, and CCL28 induced migration of plasma cells with similar potencies and efficiencies. CCL11 and CCL27 also induced modest migratory responses, while CXCL13 induced only marginal responses. The chemotactic responses of plasma cells to CCL28, which signals via both CCR10 and CCR3 (10, 11), were roughly about the summation of those to CCL27 and CCL11, the specific ligands of CCR10 and CCR3, respectively (1). These results were in good accordance with the expression profile of chemokine receptors on plasma cells (Fig. 1).



View larger version (29K):
[in this window]
[in a new window]
 
FIGURE 2. Chemotactic and adhesion responses of plasma cells. a, Migratory responses of human bone marrow plasma cells to indicated chemokines were determined in Transwell plates. After incubation for 2 h at 37°C, input cells and cells migrated into lower wells were double stained with PE-labeled anti-CD38 and Cy5-labeled anti-CD45, and measured by flow cytometry. All assays were done in duplicate. Chemotaxis index = migration in response to chemokine/background migration. Representative results of CD38highCD45low mature plasma cells from five donors are shown. Each point represents mean ± SEM from three separate experiments. b, Bone marrow mononuclear cells were resuspended without or with chemokines at 200 nM and immediately added in triplicate to 96-well plates coated with BSA or fibronectin. After washing, bound cells were harvested and stained with PE-labeled anti-CD38. Plasma cells in original and bound populations were counted by flow cytometry. For blocking experiments, cells were pretreated for 20 min with 10 µg/ml anti-integrin {alpha}4 (HP1/2) before treatment with chemokines. Representative results from three donors are shown. Each point represents mean ± SEM from three separate experiments. c, Bone marrow mononuclear cells obtained from adult donors (n = 3) were seeded in triplicate into 96-well microtest plates coated with CXCL16-SEAP or SEAP and incubated for 30 min at room temperature. In some experiments, cells were pretreated with 30 µg/ml anti-CXCR6 or 500 ng/ml pertussis toxin (PTX; Invitrogen) for 30 min, or the assay was conducted with adhesion buffer containing 5 mM EGTA. After gentle washing, original cell populations and adherent cells were stained with PE-labeled anti-CD38, and CD38high plasma cells were counted by flow cytometry. Representative results from three donors are shown. Each point represents mean ± SEM from three separate experiments.

 
Previously, CXCL12 was shown to induce transient adhesion of fresh myeloma cells to fibronectin and VCAM-1 via activation of very late Ag-4 (VLA-4) (12). Therefore, we examined whether CXCL16 and CCL28 were also capable of inducing adhesion of plasma cells to fibronectin. As shown in Fig. 2b, not only CXCL12 but also CXCL16 and CCL28 efficiently induced adhesion of bone marrow plasma cells to fibronectin. The adhesion responses were rapid and transient, reaching the maximal levels within 5 min and returning to basal levels by 30 min (12), and also VLA-4 dependent as shown by the ability of anti-{alpha}4 integrin mAb to block cell adhesion to fibronectin.

Direct adhesion of plasma cells to immobilized CXCL16

CXCL16, the ligand of CXCR6, is a novel transmembrane-type chemokine whose structure is very similar to that of another transmembrane chemokine fractalkine/CX3C chemokine ligand (CX3CL)1 (8, 9). Previously, we have shown that immobilized CX3CL1 induces firm adhesion of CX3CR1-expressing cells via its chemokine domain in both static and flow conditions without requiring signaling via G{alpha}i or divalent cations (14, 17). The structural similarity of CXCL16 to CX3CL1 prompted us to examine whether immobilized CXCL16 was also capable of inducing direct adhesion of plasma cells expressing CXCR6. As shown in Fig. 2c, CXCL16-SEAP immobilized to the plastic surface efficiently induced adhesion of plasma cells, which was effectively blocked by anti-CXCR6 but not by control Ab. Furthermore, pretreatment of plasma cells with pertussis toxin or presence of EGTA during the binding assay did not affect the levels of adhesion. Collectively, immobilized CXCL16 was indeed capable of inducing adhesion of plasma cells via CXCR6 without requiring signaling via G{alpha}i or divalent cations (integrins).

Expression of CXCL12, CXCL16, and CCL28 by human bone marrow stromal cells

The selective expression of CXCR4, CXCR6, CCR10, and CCR3 by bone marrow plasma cells suggests that their respective chemokine ligands may be involved in the homing and tissue microenvironmental localization of plasma cells in the bone marrow and other target tissues. However, except for CXCL12 (CXCR4 ligand) (7), expression of these chemokines in the bone marrow has not been reported. Therefore, we conducted RT-PCR analysis for expression of these chemokines in bone marrow and other human tissues known to be enriched with plasma cells. As shown in Fig. 3a, all the tissues examined including bone marrow expressed CXCL12 (CXCR4 ligand), CXCL16 (CXCR6 ligand), and CCL28 (CCR10 and CCR3 ligand) at high levels. Thus, these chemokines can be collectively involved in the homing and localization of plasma cells in the bone marrow and other target tissues. In contrast, CCL11 (CCR3 ligand) or CCL27 (CCR10 ligand) was hardly expressed in the bone marrow.



View larger version (31K):
[in this window]
[in a new window]
 
FIGURE 3. Expression of CXCL12, CXCL16, and CCL28 in human bone marrow tissue and stromal cells. a, cDNA samples from PHA-stimulated PBMC (positive control), human bone marrow, spleen, lymph node, tonsil, small intestine, and colon were analyzed for expression of CXCL12, CXCL16, CCL11, CCL27, CCL28, and G3PDH by PCR. Representative results from two separate experiments are shown. b, cDNA samples from PHA-stimulated PBMC (positive control) and human bone marrow stromal cells treated without or with 10 ng/ml IL-1{beta}, 50 ng/ml TNF-{alpha}, 100 ng/ml IFN-{gamma}, 10 ng/ml IL-4, 10 ng/ml IL-6, 10 ng/ml TGF-{beta}, and 10 ng/ml GM-CSF for 24 h were analyzed for expression of CXCL12, CXCL16, CCL28, and G3PDH by real-time PCR. Representative results from two separate experiments are shown. c, Bone marrow stromal cells were seeded in triplicate in 24-well plates and cultured without or with 10 ng/ml IL-1{beta}. At indicated time points, CXCL12 and CCL28 in the culture supernatants were measured by using ELISA. Each point represents mean ± SEM. Representative results from two separate experiments are shown.

 
CXCL12 was originally identified as a secretory product of a mouse bone marrow stromal cell line (7). Therefore, we next examined expression of CXCL12, CXCL16, and CCL28 by human primary bone marrow stromal cells. We confirmed that stromal cells were CD10+ and CD34low (data not shown) (18). As shown in Fig. 3b, real-time RT-PCR revealed that stromal cells indeed constitutively expressed CXCL12, CXCL16, and CCL28 at high levels. The expression of CXCL12 was enhanced by treatment with IL-1{beta}, TNF-{alpha}, or IFN-{gamma}, while that of CXCL16 was enhanced by IFN-{gamma}. In contrast, the expression of CCL28 was hardly affected by any cytokines. We also examined secretion of CXCL12 and CCL28 by bone marrow stromal cells. As shown in Fig. 3c, stromal cells indeed secreted copious amounts of CXCL12 and CCL28 in the culture supernatants. Consistent with the results from RT-PCR (Fig. 3b), treatment of stromal cells with IL-1{beta} significantly enhanced secretion of CXCL12 (p < 0.05) but not that of CCL28.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We have demonstrated that human bone marrow plasma cells as well as myeloma cells consistently express CXCR4, CXCR6, CCR10, and CCR3 (Fig. 1). Accordingly, CXCL12 (CXCR4 ligand) (7), CXCL16 (CXCR6 ligand) (8, 9), and CCL28 (CCR10 and CCR3 ligand) (10, 11) efficiently induced chemotactic responses and VLA-4-dependent transient adhesion to fibronectin in plasma cells (Fig. 2). Importantly, we have also shown that human bone marrow and other tissues known to be enriched with plasma cells contain transcripts of CXCL12, CXCL16, and CCL28 at high levels (Fig. 3). Furthermore, we have shown that cultured human bone marrow stromal cells constitutively express CXCL12, CXCL16, and CCL28 at high levels (Fig. 3). Collectively, our results support the roles of CXCR4, CXCR6, CCR10, and CCR3 and their respective chemokine ligands in the migration and tissue localization of human plasma cells in bone marrow and other tissues known to be enriched with plasma cells.

CXCL16 is a novel transmembrane-type chemokine (8, 9), which was also identified as a novel scavenger receptor for oxidized low density lipoprotein (13). In the present study, we have shown that immobilized CXCL16 is capable of inducing adhesion of plasma cells expressing CXCR6 without requiring G{alpha}i-mediated signaling or divalent cations (Fig. 2), an observation quite similar to that of another transmembrane-type chemokine CX3CL1 (14, 17). Thus, like CX3CL1, CXCL16 may function as a chemoattractant in its soluble form and a cell adhesion molecule in its membrane-anchored form. This may allow CXCL16 to contribute to plasma cell localization in the bone marrow and other target tissues not only by its chemotactic activity but also by its direct cell adhering activity.

In conclusion, we have shown for the first time that human bone marrow plasma cells and myeloma cells consistently express CXCR6, CCR10, and CCR3 besides CXCR4. The important role of CXCR4 in migration and tissue localization of plasma cells has been reported previously (2). Thus, the exact roles of CXCR6, CCR10, and CCR3 in the migration and tissue localization of plasma cells remain to be seen. It also remains to be seen whether human plasma cells producing different Ig isotypes express a different set of chemokine receptors to migrate to different anatomical sites as mouse plasma cells do (4).


    Acknowledgments
 
We thank Shin Yonehara for providing cDNA for CXCL16/SR-PSOX.


    Footnotes
 
1 This work was supported in part by Grants-in-Aid for Science Research and a High-Tech Research Center Grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and by Solution Oriented Research for Science and Technology of the Japan Science and Technology Corporation. Back

2 Address correspondence to Dr. Osamu Yoshie, Department of Microbiology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. E-mail address: o.yoshie{at}med.kindai.ac.jp Back

3 Abbreviations used in this paper: CXCL, CXC chemokine ligand; CCL, CC chemokine ligand; CX3CL, CX3C chemokine ligand; VLA-4, very late Ag-4; SEAP, secreted form of placental alkaline phosphatase. Back

Received for publication October 8, 2002. Accepted for publication November 27, 2002.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Yoshie, O., T. Imai, H. Nomiyama. 2001. Chemokines in immunity. Adv. Immunol. 78:57.[Medline]
  2. Hargreaves, D. C., P. L. Hyman, T. T. Lu, V. N. Ngo, A. Bidgol, G. Suzuki, Y. R. Zou, D. R. Littman, J. G. Cyster. 2001. A coordinated change in chemokine responsiveness guides plasma cell movements. J. Exp. Med. 194:45.[Abstract/Free Full Text]
  3. Wehrli, N., D. F. Legler, D. Finke, K. M. Toellner, P. Loetscher, M. Baggiolini, I. C. MacLennan, H. Acha-Orbea. 2001. Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. Eur. J. Immunol. 31:609.[Medline]
  4. Bowman, E. P., N. A. Kuklin, K. R. Youngman, N. H. Lazarus, E. J. Kunkel, J. Pan, H. B. Greenberg, E. C. Butcher. 2002. The intestinal chemokinethymus-expressed chemokine (CCL25) attracts IgA antibody-secreting cells. J. Exp. Med. 195:269.[Abstract/Free Full Text]
  5. Nakayama, T., R. Fujisawa, D. Izawa, K. Hieshima, K. Takada, O. Yoshie. 2002. Human B cells immortalized with Epstein-Barr virus upregulate CCR6 and CCR10 and downregulate CXCR4 and CXCR5. J. Virol. 76:3072.[Abstract/Free Full Text]
  6. Bowman, E. P., J. J. Campbell, D. Soler, Z. Dong, N. Manlongat, D. Picarella, R. R. Hardy, E. C. Butcher. 2000. Developmental switches in chemokine response profiles during B cell differentiation and maturation. J. Exp. Med. 191:1303.[Abstract/Free Full Text]
  7. Tashiro, K., H. Tada, R. Heilker, M. Shirozu, T. Nakano, T. Honjo. 1993. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 261:600.[Abstract/Free Full Text]
  8. Matloubian, M., A. David, S. Engel, J. E. Ryan, J. G. Cyster. 2000. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 1:298.[Medline]
  9. Wilbanks, A., S. C. Zondlo, K. Murphy, S. Mak, D. Soler, P. Langdon, D. P. Andrew, L. Wu, M. Briskin. 2001. Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J. Immunol. 166:5145.[Abstract/Free Full Text]
  10. Wang, W., H. Soto, E. R. Oldham, M. E. Buchanan, B. Homey, D. Catron, N. Jenkins, N. G. Copeland, D. J. Gilbert, N. Nguyen, et al 2000. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2). J. Biol. Chem. 275:22313.[Abstract/Free Full Text]
  11. Pan, J., E. J. Kunkel, U. Gosslar, N. Lazarus, P. Langdon, K. Broadwell, M. A. Vierra, M. C. Genovese, E. C. Butcher, D. Soler. 2000. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J. Immunol. 165:2943.[Abstract/Free Full Text]
  12. Sanz-Rodriguez, F., A. Hidalgo, J. Teixido. 2001. Chemokine stromal cell-derived factor-1{alpha} modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 97:346.[Abstract/Free Full Text]
  13. Shimaoka, T., N. Kume, M. Minami, K. Hayashida, H. Kataoka, T. Kita, S. Yonehara. 2000. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J. Biol. Chem. 275:40663.[Abstract/Free Full Text]
  14. Imai, T., K. Hieshima, C. Haskell, M. Baba, M. Nagira, M. Nishimura, M. Kakizaki, S. Takagi, H. Nomiyama, T. J. Schall, O. Yoshie. 1997. Identification and molecular characterization of a fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91:521.[Medline]
  15. O’Connor, B. P., M. Cascalho, R. J. Noelle. 2002. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J. Exp. Med. 195:737.[Abstract/Free Full Text]
  16. Ruiz-Arguelles, G. J., J. F. San Miguel. 1994. Cell surface markers in multiple myeloma. Mayo Clin. Proc. 69:684.[Medline]
  17. Fong, A. M., L. A. Robinson, D. A. Steeber, T. F. Tedder, O. Yoshie, T. Imai, D. D. Patel. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188:1413.[Abstract/Free Full Text]
  18. Clark, B. R., A. Keating. 1995. Biology of bone marrow stroma. Ann. NY Acad. Sci. 770:70.[Medline]



This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
P. Gutwein, M. S. Abdel-Bakky, A. Schramme, K. Doberstein, N. Kampfer-Kolb, K. Amann, I. A. Hauser, N. Obermuller, C. Bartel, A.-A. H. Abdel-Aziz, et al.
CXCL16 Is Expressed in Podocytes and Acts as a Scavenger Receptor for Oxidized Low-Density Lipoprotein
Am. J. Pathol., June 1, 2009; 174(6): 2061 - 2072.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
A W T van Lieshout, R van der Voort, L W J Toonen, S F G van Helden, C G Figdor, P L C M van Riel, T R D J Radstake, and G J Adema
Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis
Ann Rheum Dis, June 1, 2009; 68(6): 1036 - 1043.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. K. Azab, J. M. Runnels, C. Pitsillides, A.-S. Moreau, F. Azab, X. Leleu, X. Jia, R. Wright, B. Ospina, A. L. Carlson, et al.
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Blood, April 30, 2009; 113(18): 4341 - 4351.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Wang, Y. Lu, J. Wang, A. E. Koch, J. Zhang, and R. S. Taichman
CXCR6 Induces Prostate Cancer Progression by the AKT/Mammalian Target of Rapamycin Signaling Pathway
Cancer Res., December 15, 2008; 68(24): 10367 - 10377.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
I. Airoldi, C. Cocco, N. Giuliani, M. Ferrarini, S. Colla, E. Ognio, G. Taverniti, E. Di Carlo, G. Cutrona, V. Perfetti, et al.
Constitutive expression of IL-12R{beta}2 on human multiple myeloma cells delineates a novel therapeutic target
Blood, August 1, 2008; 112(3): 750 - 759.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
Y. Lu, J. Wang, Y. Xu, A. E. Koch, Z. Cai, X. Chen, D. L. Galson, R. S. Taichman, and J. Zhang
CXCL16 Functions as a Novel Chemotactic Factor for Prostate Cancer Cells In vitro
Mol. Cancer Res., April 1, 2008; 6(4): 546 - 554.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. J. J. de Gorter, R. M. Reijmers, E. A. Beuling, H. P. H. Naber, A. Kuil, M. J. Kersten, S. T. Pals, and M. Spaargaren
The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells
Blood, April 1, 2008; 111(7): 3364 - 3372.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A.-K. Shirakawa, D. Nagakubo, K. Hieshima, T. Nakayama, Z. Jin, and O. Yoshie
1,25-Dihydroxyvitamin D3 Induces CCR10 Expression in Terminally Differentiating Human B Cells
J. Immunol., March 1, 2008; 180(5): 2786 - 2795.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X. Leleu, X. Jia, J. Runnels, H. T. Ngo, A.-S. Moreau, M. Farag, J. A. Spencer, C. M. Pitsillides, E. Hatjiharissi, A. Roccaro, et al.
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
Blood, December 15, 2007; 110(13): 4417 - 4426.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. T. Pals, D. J. J. de Gorter, and M. Spaargaren
Lymphoma dissemination: the other face of lymphocyte homing
Blood, November 1, 2007; 110(9): 3102 - 3111.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. Galkina, B. L. Harry, A. Ludwig, E. A. Liehn, J. M. Sanders, A. Bruce, C. Weber, and K. Ley
CXCR6 Promotes Atherosclerosis by Supporting T-Cell Homing, Interferon-{gamma} Production, and Macrophage Accumulation in the Aortic Wall
Circulation, October 16, 2007; 116(16): 1801 - 1811.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
A. W T van Lieshout, J. Fransen, M. Flendrie, A. M M Eijsbouts, F. H J van den Hoogen, P. L C M van Riel, and T. R D J Radstake
Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis
Ann Rheum Dis, October 1, 2007; 66(10): 1334 - 1338.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Muehlenbachs, M. Fried, J. Lachowitzer, T. K. Mutabingwa, and P. E. Duffy
Genome-Wide Expression Analysis of Placental Malaria Reveals Features of Lymphoid Neogenesis during Chronic Infection
J. Immunol., July 1, 2007; 179(1): 557 - 565.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
U. Koedel, U. M. Merbt, C. Schmidt, B. Angele, B. Popp, H. Wagner, H.-W. Pfister, and C. J. Kirschning
Acute Brain Injury Triggers MyD88-Dependent, TLR2/4-Independent Inflammatory Responses
Am. J. Pathol., July 1, 2007; 171(1): 200 - 213.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Alsayed, H. Ngo, J. Runnels, X. Leleu, U. K. Singha, C. M. Pitsillides, J. A. Spencer, T. Kimlinger, J. M. Ghobrial, X. Jia, et al.
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma
Blood, April 1, 2007; 109(7): 2708 - 2717.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Nadav, B.-Z. Katz, S. Baron, N. Cohen, E. Naparstek, and B. Geiger
The Generation and Regulation of Functional Diversity of Malignant Plasma Cells.
Cancer Res., September 1, 2006; 66(17): 8608 - 8616.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Feng, M. C. Jaimes, N. H. Lazarus, D. Monak, C. Zhang, E. C. Butcher, and H. B. Greenberg
Redundant Role of Chemokines CCL25/TECK and CCL28/MEC in IgA+ Plasmablast Recruitment to the Intestinal Lamina Propria After Rotavirus Infection
J. Immunol., May 15, 2006; 176(10): 5749 - 5759.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
Y. Huang, X.-Y. Zhu, M.-R. Du, X. Wu, M.-Y. Wang, and D.-J. Li
Chemokine CXCL16, a scavenger receptor, induces proliferation and invasion of first-trimester human trophoblast cells in an autocrine manner
Hum. Reprod., April 1, 2006; 21(4): 1083 - 1091.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. A. Burger and T. J. Kipps
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
Blood, March 1, 2006; 107(5): 1761 - 1767.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Hase, T. Murakami, H. Takatsu, T. Shimaoka, M. Iimura, K. Hamura, K. Kawano, S. Ohshima, R. Chihara, K. Itoh, et al.
The Membrane-Bound Chemokine CXCL16 Expressed on Follicle-Associated Epithelium and M Cells Mediates Lympho-Epithelial Interaction in GALT
J. Immunol., January 1, 2006; 176(1): 43 - 51.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Sordi, M. L. Malosio, F. Marchesi, A. Mercalli, R. Melzi, T. Giordano, N. Belmonte, G. Ferrari, B. E. Leone, F. Bertuzzi, et al.
Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets
Blood, July 15, 2005; 106(2): 419 - 427.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
H. Xu, W. Xu, Y. Chu, Y. Gong, Z. Jiang, and S. Xiong
Involvement of Up-Regulated CXC Chemokine Ligand 16/Scavenger Receptor That Binds Phosphatidylserine and Oxidized Lipoprotein in Endotoxin-Induced Lethal Liver Injury via Regulation of T-Cell Recruitment and Adhesion
Infect. Immun., July 1, 2005; 73(7): 4007 - 4016.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. H. A. Rayes, A. C. Rawstron, G. J. Morgan, and F. E. Davies
The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells
Blood, June 15, 2005; 105(12): 4895 - 4896.
[Full Text] [PDF]


Home page
BloodHome page
G. Muehlinghaus, L. Cigliano, S. Huehn, A. Peddinghaus, H. Leyendeckers, A. E. Hauser, F. Hiepe, A. Radbruch, S. Arce, and R. A. Manz
Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells
Blood, May 15, 2005; 105(10): 3965 - 3971.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. T. Avery, J. I. Ellyard, F. Mackay, L. M. Corcoran, P. D. Hodgkin, and S. G. Tangye
Increased Expression of CD27 on Activated Human Memory B Cells Correlates with Their Commitment to the Plasma Cell Lineage
J. Immunol., April 1, 2005; 174(7): 4034 - 4042.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. C.W. Zannettino, A. N. Farrugia, A. Kortesidis, J. Manavis, L. B. To, S. K. Martin, P. Diamond, H. Tamamura, T. Lapidot, N. Fujii, et al.
Elevated Serum Levels of Stromal-Derived Factor-1{alpha} Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients
Cancer Res., March 1, 2005; 65(5): 1700 - 1709.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Sato, H. Thorlacius, B. Johnston, T. L. Staton, W. Xiang, D. R. Littman, and E. C. Butcher
Role for CXCR6 in Recruitment of Activated CD8+ Lymphocytes to Inflamed Liver
J. Immunol., January 1, 2005; 174(1): 277 - 283.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. F. Charo and M. B. Taubman
Chemokines in the Pathogenesis of Vascular Disease
Circ. Res., October 29, 2004; 95(9): 858 - 866.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. C. Jaimes, O. L. Rojas, E. J. Kunkel, N. H. Lazarus, D. Soler, E. C. Butcher, D. Bass, J. Angel, M. A. Franco, and H. B. Greenberg
Maturation and Trafficking Markers on Rotavirus-Specific B Cells during Acute Infection and Convalescence in Children
J. Virol., October 15, 2004; 78(20): 10967 - 10976.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
T. Kukita, N. Wada, A. Kukita, T. Kakimoto, F. Sandra, K. Toh, K. Nagata, T. Iijima, M. Horiuchi, H. Matsusaki, et al.
RANKL-induced DC-STAMP Is Essential for Osteoclastogenesis
J. Exp. Med., October 4, 2004; 200(7): 941 - 946.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
J J Haringman, J Ludikhuize, and P P Tak
Chemokines in joint disease: the key to inflammation?
Ann Rheum Dis, October 1, 2004; 63(10): 1186 - 1194.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
E. Wilson and E. C. Butcher
CCL28 Controls Immunoglobulin (Ig)A Plasma Cell Accumulation in the Lactating Mammary Gland and IgA Antibody Transfer to the Neonate
J. Exp. Med., September 20, 2004; 200(6): 805 - 809.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Hieshima, Y. Kawasaki, H. Hanamoto, T. Nakayama, D. Nagakubo, A. Kanamaru, and O. Yoshie
CC Chemokine Ligands 25 and 28 Play Essential Roles in Intestinal Extravasation of IgA Antibody-Secreting Cells
J. Immunol., September 15, 2004; 173(6): 3668 - 3675.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. V. Gulino, D. Moratto, S. Sozzani, P. Cavadini, K. Otero, L. Tassone, L. Imberti, S. Pirovano, L. D. Notarangelo, R. Soresina, et al.
Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome
Blood, July 15, 2004; 104(2): 444 - 452.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Abel, C. Hundhausen, R. Mentlein, A. Schulte, T. A. Berkhout, N. Broadway, D. Hartmann, R. Sedlacek, S. Dietrich, B. Muetze, et al.
The Transmembrane CXC-Chemokine Ligand 16 Is Induced by IFN-{gamma} and TNF-{alpha} and Shed by the Activity of the Disintegrin-Like Metalloproteinase ADAM10
J. Immunol., May 15, 2004; 172(10): 6362 - 6372.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Daoudi, E. Lavergne, A. Garin, N. Tarantino, P. Debre, F. Pincet, C. Combadiere, and P. Deterre
Enhanced Adhesive Capacities of the Naturally Occurring Ile249-Met280 Variant of the Chemokine Receptor CX3CR1
J. Biol. Chem., May 7, 2004; 279(19): 19649 - 19657.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H. Hanamoto, T. Nakayama, H. Miyazato, S. Takegawa, K. Hieshima, Y. Tatsumi, A. Kanamaru, and O. Yoshie
Expression of CCL28 by Reed-Sternberg Cells Defines a Major Subtype of Classical Hodgkin's Disease with Frequent Infiltration of Eosinophils and/or Plasma Cells
Am. J. Pathol., March 1, 2004; 164(3): 997 - 1006.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
T. Nakayama, K. Hieshima, D. Nagakubo, E. Sato, M. Nakayama, K. Kawa, and O. Yoshie
Selective Induction of Th2-Attracting Chemokines CCL17 and CCL22 in Human B Cells by Latent Membrane Protein 1 of Epstein-Barr Virus
J. Virol., February 15, 2004; 78(4): 1665 - 1674.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
T. Shimaoka, T. Nakayama, N. Fukumoto, N. Kume, S. Takahashi, J. Yamaguchi, M. Minami, K. Hayashida, T. Kita, J. Ohsumi, et al.
Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells
J. Leukoc. Biol., February 1, 2004; 75(2): 267 - 274.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Chandrasekar, S. Bysani, and S. Mummidi
CXCL16 Signals via Gi, Phosphatidylinositol 3-Kinase, Akt, I{kappa}B Kinase, and Nuclear Factor-{kappa}B and Induces Cell-Cell Adhesion and Aortic Smooth Muscle Cell Proliferation
J. Biol. Chem., January 30, 2004; 279(5): 3188 - 3196.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
Y. Ueda, K. Yang, S. J. Foster, M. Kondo, and G. Kelsoe
Inflammation Controls B Lymphopoiesis by Regulating Chemokine CXCL12 Expression
J. Exp. Med., January 5, 2004; 199(1): 47 - 58.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. H. Underhill, K. P. Kolli, and G. S. Kansas
Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation
Blood, December 1, 2003; 102(12): 4076 - 4083.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakayama, T.
Right arrow Articles by Yoshie, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakayama, T.
Right arrow Articles by Yoshie, O.
Right arrowPubmed/NCBI databases
*Substance via MeSH


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS